论文部分内容阅读
近年来随着医学的不断发展,对甘露醇作用机制的深入研究与更新认识,其临床应用日益拓宽,口服用药更为广泛,本文就其在心脑血管疾病的应用作一浅述。 1 治疗心血管疾病 1.1 急性心肌梗死(AMI)再灌注心律失常 丁东,付道存报道对静脉再通疗法(IVCR)后再灌注心律失常(RA)发生率高进行研究,认为与氧自由基的大量产生有关。该资料应用尿激酶100U(1h滴完)后,用20％甘露醇0.5g/kg～1.0g/kg,10滴/min～15滴/min,静脉滴注,预防AMI再灌注心律失常,以症状、心电图、心肌酶及溶栓再通标准衡量。结果:治疗组21例中,静脉再通疗法16例,其中发生再灌注心律失常6例,占静脉再通疗法患者的37.5％;对照组20例,静脉再通疗法14例,发生再灌注心律失常12例,发生率85.7％,两组差异极显著(P<0.01)。 1.2 顽固性心绞痛 甘露醇对心肌缺血时产生的
In recent years, with the continuous development of medicine, the in-depth study and update of the mechanism of mannitol have widened its clinical application and become more widely used in oral medicine. This article gives a brief account of its application in cardiovascular and cerebrovascular diseases. 1 Treatment of Cardiovascular Disease 1.1 Reperfusion Arrhythmia with Acute Myocardial Infarction (AMI) Ding Dong and Fu Dao-cun reported that the high incidence of reperfusion arrhythmia (RA) after intravenous recanalization (IVCR) Generate a large number of related. The data application of urokinase 100U (1h End), with 20% mannitol 0.5g / kg ~ 1.0g / kg, 10 drops / min ~ 15 drops / min, intravenous infusion, to prevent AMI reperfusion arrhythmias Symptoms, ECG, myocardial enzymes and thrombolytic recanalization standards. Results: In the 21 cases of treatment group, 16 cases were recanalized intravenously, including 6 cases of reperfusion arrhythmia, accounting for 37.5% of patients receiving intravenous recanalization therapy; 20 cases of control group and 14 cases of recanalization therapy, In 12 cases, the incidence rate was 85.7%. There was significant difference between the two groups (P <0.01). 1.2 Stubborn angina mannitol produced on myocardial ischemia